COCH Form 4 reports purchase transactions

TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH.

Rhea-AI Filing Summary

TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 48,750,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 11,250,000 shares.

Insights

Equity ownership and governance analyst

Large insider purchases increase this 10% holder’s direct and warrant exposure.

Glen A. Taylor, identified as a 10% owner of Envoy Medical, bought 18,750,000 Class A shares at $0.40 on 02/12/2026. He also acquired 11,250,000 Series A-1 and 18,750,000 Series A-2 warrants with a $0.40 exercise price, materially expanding his potential stake.

The warrants only become exercisable after stockholders approve issuing the underlying shares, and they expire based on the stockholder approval date and specific FDA milestones for the Acclaim cochlear implant. Actual dilution and ownership outcomes therefore depend on future stockholder approval and regulatory events rather than this filing alone.

Insider Trade Summary

Net Buyer: 48,750,000 shares

Net Buy 5 txns

Insider TAYLOR GLEN A

Role 10% Owner

Bought 48,750,000 shs ($7.50M)

Type	Security	Shares	Price	Value
Purchase	Warrant Shares (Series A-1)	11,250,000	$0.00	$0.00
Purchase	Warrant Shares (Series A-2)	18,750,000	$0.00	$0.00
Purchase	Class A Common Stock	18,750,000	$0.40	$7.50M
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Warrant Shares (Series A-1) — 11,250,000 contracts (Direct); Warrant Shares (Series A-2) — 18,750,000 contracts (Direct); Class A Common Stock — 21,703,607 shares (Direct); Class A Common Stock — 2,526,058 shares (Indirect, By Taylor Sports Group); Class A Common Stock — 4,810,384 shares (Indirect, By GAT Funding, LLC)

Footnotes (5)

1. F1. The Reporting Person is the owner and chairman of Taylor Sports Group.
2. F2. GAT Funding, LLC is an entity controlled by Reporting Person.
3. F3. The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").
4. F4. The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event").
5. F5. The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event").

FAQ

What did Glen A. Taylor report in this Form 4 for Envoy Medical (COCH)?

Glen A. Taylor reported large purchases of Envoy Medical securities. He bought 18,750,000 Class A common shares at $0.40 and acquired Series A-1 and A-2 warrants covering 29, ,000 shares in total, significantly increasing his potential ownership stake in the company.

How many Envoy Medical Class A shares did Glen A. Taylor buy and at what price?

He bought 18,750,000 Envoy Medical Class A common shares at $0.40 each. The transaction, dated February 12, 2026, is classified as an open-market or private purchase, and raised his directly held Class A shares to 21,703,607 after the reported transaction.

What warrant positions did Glen A. Taylor acquire in Envoy Medical (COCH)?

Taylor acquired 11,250,000 Series A-1 and 18,750,000 Series A-2 common stock warrants, each series with a $0.40 exercise price. Together they cover 30,000,000 underlying Class A shares and become exercisable only after stockholders approve issuing those underlying shares.

When do Envoy Medical’s Series A-1 and Series A-2 warrants held by Taylor expire?

Series A-1 warrants expire the earlier of 24 months after stockholder approval or 30 days after a PMA filing announcement for the Acclaim implant. Series A-2 warrants expire 60 months after approval or 30 days after an FDA approval announcement.

Does Glen A. Taylor have any indirect ownership in Envoy Medical (COCH)?

Yes. He is owner and chairman of Taylor Sports Group, which holds 2,526,058 Class A shares, and he controls GAT Funding, LLC, which holds 4,810,384 Class A shares. These positions are reported as indirect beneficial ownership on the Form 4.

What conditions must be met before Taylor’s Envoy Medical warrants can be exercised?

Both Series A-1 and Series A-2 warrants become exercisable only after the effective date of stockholder approval for issuing the shares upon warrant exercise. Until that stockholder approval is effective, the common warrants cannot be exercised for Envoy Medical Class A shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 01:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAYLOR GLEN A

(Last) (First) (Middle)

C/O TAYLOR CORP, 1725 ROE CREST DR

(Street)

N MANKALO MN 56002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Envoy Medical, Inc. [ COCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								2,526,058	I	By Taylor Sports Group(1)
Class A Common Stock								4,810,384	I	By GAT Funding, LLC(2)
Class A Common Stock	02/12/2026		P		18,750,000	A	$0.4	21,703,607	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant Shares (Series A-1)	$0.4	02/12/2026		P		11,250,000		(3)	(4)	Class A Common Stock	11,250,000	$0	11,250,000	D
Warrant Shares (Series A-2)	$0.4	02/12/2026		P		18,750,000		(3)	(5)	Class A Common Stock	18,750,000	$0	18,750,000	D

Explanation of Responses:

1. The Reporting Person is the owner and chairman of Taylor Sports Group.

2. GAT Funding, LLC is an entity controlled by Reporting Person.

3. The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").

4. The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event").

5. The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event").

	/s/ Glen A. Taylor	02/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.